Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
LungLife AI, Inc. ( (GB:LLAI) ) just unveiled an update.
LungLife AI, Inc. has entered into an exclusive license and distribution agreement with Circulogene Theranostics, Inc. for the commercial distribution of its LungLB® test in the U.S. This agreement involves an upfront payment and future royalty payments, with an option for Circulogene to purchase the licensed intellectual property. The deal is contingent upon obtaining necessary consents, including shareholder approval. The agreement is expected to provide financial stability and extend LungLife’s operational capabilities, while also potentially impacting the company’s market positioning and future strategic decisions.
More about LungLife AI, Inc.
LungLife AI, Inc. is a company operating in the clinical diagnostics industry, focusing on developing solutions for lung cancer detection. Their primary product is the LungLB® test, which is aimed at improving early detection and management of lung cancer. The company is particularly focused on the U.S. market through strategic partnerships.
YTD Price Performance: -89.41%
Average Trading Volume: 359,269
Technical Sentiment Signal: Buy
For detailed information about LLAI stock, go to TipRanks’ Stock Analysis page.